Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Folic Acid Supplementation in Patients with Elevated Homocysteine Levels

INTRODUCTION: Folic acid is the most important dietary determinant of homocysteine (Hcy). Hcy serves as a critical intermediate in methylation reactions. It is created from methionine and either converted back to methionine or transformed into cysteine. This process is aided through several enzymes and three vitamins, folic acid, B12, and B6. Daily supplementation with 0.5-5.0 mg of folic acid typically lowers plasma Hcy levels by approximately 25%. Hyperhomocysteinemia is a known risk factor for coronary artery disease. In this regard, elevated levels of Hcy have been found in a majority of patients with vascular disease

METHODS: A literature review of folic acid supplementation for various disease states including cardiovascular disease was conducted. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors

RESULTS: In this review, we discuss the biochemistry of folic acid, Hcy biosynthesis, Hcy and hydrogen sulfide bioavailability, pathogenesis of hyperhomocysteinemia and its role as a risk factor for disease, and treatment studies with folic acid supplementation in disease states

CONCLUSION: Folic acid supplementation should be recommended to any patient who has an elevated Hcy level, and this level should be measured and treated at an early age, since folic acid is easily obtained and may likely reduce vascular disease and other deleterious pathologic processes in high-risk populations

Year of Publication: 2020
Contained in: Advances in therapy Vol. 37, No. 10 (2020), p. 4149-4164
All journal articles: Search for all articles in this journal
Language: English
Contributors: Kaye, Alan D | Author
Jeha, George M
Pham, Alex D
Fuller, Mitchell C
Lerner, Zachary I
Sibley, Gerald T
Cornett, Elyse M
Urits, Ivan
Viswanath, Omar
Kevil, Christopher G
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Coronary artery disease
Folic acid
Heart disease
Homocysteine
Hyperhomocysteinemia
Journal Article
Review
ISSN: 1865-8652
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 01.10.2020
published: Print-Electronic
Citation Status In-Data-Review
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32845472
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s12325-020-01474-z
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03439nma a2200637 c 4500
001 NLM315130199
003 DE-601
005 20201001214650.0
007 cr uuu---uuuuu
008 200826s2020 000 0 eng d
024 7 |a 10.1007/s12325-020-01474-z  |2 doi 
028 5 2 |a pubmed20n1410.xml 
035 |a (DE-599)NLM32845472 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Kaye, Alan D 
245 1 0 |a Folic Acid Supplementation in Patients with Elevated Homocysteine Levels  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 01.10.2020 
500 |a published: Print-Electronic 
500 |a Citation Status In-Data-Review 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a INTRODUCTION: Folic acid is the most important dietary determinant of homocysteine (Hcy). Hcy serves as a critical intermediate in methylation reactions. It is created from methionine and either converted back to methionine or transformed into cysteine. This process is aided through several enzymes and three vitamins, folic acid, B12, and B6. Daily supplementation with 0.5-5.0 mg of folic acid typically lowers plasma Hcy levels by approximately 25%. Hyperhomocysteinemia is a known risk factor for coronary artery disease. In this regard, elevated levels of Hcy have been found in a majority of patients with vascular disease 
520 |a METHODS: A literature review of folic acid supplementation for various disease states including cardiovascular disease was conducted. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors 
520 |a RESULTS: In this review, we discuss the biochemistry of folic acid, Hcy biosynthesis, Hcy and hydrogen sulfide bioavailability, pathogenesis of hyperhomocysteinemia and its role as a risk factor for disease, and treatment studies with folic acid supplementation in disease states 
520 |a CONCLUSION: Folic acid supplementation should be recommended to any patient who has an elevated Hcy level, and this level should be measured and treated at an early age, since folic acid is easily obtained and may likely reduce vascular disease and other deleterious pathologic processes in high-risk populations 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
655 7 |a Coronary artery disease  |2 gnd 
655 7 |a Folic acid  |2 gnd 
655 7 |a Heart disease  |2 gnd 
655 7 |a Homocysteine  |2 gnd 
655 7 |a Hyperhomocysteinemia  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Coronary artery disease 
689 1 1 |a Folic acid 
689 1 2 |a Heart disease 
689 1 3 |a Homocysteine 
689 1 4 |a Hyperhomocysteinemia 
689 1 |5 DE-601 
700 1 |a Jeha, George M 
700 1 |a Pham, Alex D 
700 1 |a Fuller, Mitchell C 
700 1 |a Lerner, Zachary I 
700 1 |a Sibley, Gerald T 
700 1 |a Cornett, Elyse M 
700 1 |a Urits, Ivan 
700 1 |a Viswanath, Omar 
700 1 |a Kevil, Christopher G 
773 0 8 |i in  |t Advances in therapy  |g Vol. 37, No. 10 (2020), p. 4149-4164  |q 37:10<4149-4164  |w (DE-601)NLM085861464  |x 1865-8652 
856 4 1 |u http://dx.doi.org/10.1007/s12325-020-01474-z  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 37  |j 2020  |e 10  |b 25  |c 10  |h 4149-4164